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Whether presence or history of extracolonic primary malignancy is a risk for colorectal neoplasia is 
not fully known.  In this study,  26,452 ﬁrst-time colonoscopy cases were examined using a colonoscopy 
database.  Among the analyzed subjects,  3,026 (11ｵ) subjects had history or concomitance of extraco-
lonic primary malignancy,  while the remaining 23,426 subjects did not.  Colorectal neoplasia was 
observed in 39ｵ of all the subjects.  A crude comparison showed that the prevalence of any type of 
colorectal neoplasia was higher in subjects with extracolonic malignancy than in those without (42ｵ 
vs. 39ｵ,  p＝0.0012).  However,  after adjusting for confounding factors,  the odds ratios (ORs) of sub-
jects with extracolonic malignancy for having colorectal neoplasia,  advanced neoplasia,  and cancer 
were all less than 1.0,  and all signiﬁcantly diﬀerent from those of subjects without extracolonic malig-
nancy.  Analysis according to the type of extracolonic malignancy revealed that gastric cancer cases 
had a signiﬁcantly lower risk for colorectal advanced neoplasia (OR: 0.81; 95ｵ CI: 0.67-0.99).  Among 
major malignancies,  only esophageal squamous cell cancer cases had increased risk for colorectal 
neoplasia (OR: 1.66; 95ｵ CI: 1.20-2.29).  Patients with presence or history of extracolonic malignancy 
did not carry a higher risk of occurrence of colorectal neoplasia.
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olorectal cancer (CRC) is one of the leading 
causes of cancer deaths in many countries,  and 
thus a plethora of reports exist regarding risk factors 
for CRC and colorectal premalignant lesions [1].  In 
particular,  smoking and drinking habits [2,  3],  red 
meat consumption [4],  obesity [5],  diabetes [6],  and 
family history of CRC [7] have been shown to be 
deﬁnite clinical risk factors for CRC.  However,  
although many of the risk factors such as smoking are 
common among cancers originating from various 
organs [8],  it is largely unknown whether presence 
and history of extracolonic primary cancer/malignancy 
is a risk for colorectal neoplasia including CRC.  If so,  
a specialized CRC screening strategy for the patients 
who have or had other primary malignancies may be 
required.
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　 In this study,  we examined whether presence or 
history of extracolonic primary cancer is a risk for 
colorectal neoplasia using a large colonoscopy data-
base registered in hospitals across Japan.
Materials and Methods
　 Study design. We have maintained a multi-
center colonoscopy database since 2003.  This data-
base includes clinical data on all patients who under-
went colonoscopy at Okayama University Hospital and 
18 aﬃliated hospitals.  The collected data included 
age,  gender,  indications for colonoscopy,  past and 
family history of colorectal cancer,  history or con-
comitance of primary malignancies of other organs,  
and the location,  size,  and histology of polyps or 
cancer found by colonoscopy.  Data input was per-
formed by the individual colonoscopist,  or,  at a few 
institutes,  by nurses or assistants.
　 From June 2005 to May 2009,  results from a total 
of 105,612 colonoscopies were registered into this 
database.  Among these,  38,786 ﬁrst-time colonoscopy 
cases were initially considered eligible for this study.  
The exclusion criteria included cases less than 20 
years of age,  with prior resection of any part of the 
colon,  with familial adenomatous polyposis or heredi-
tary nonpolyposis colorectal cancer,  with inﬂamma-
tory bowel disease,  and whose data lacked clinical 
information or histological information on polyps.  
After excluding these subjects,  26,452 cases were 
analyzed.
　 In this analysis,  we examined colonoscopic ﬁndings 
according to the status of extracolonic malignancy.  
Subjects were divided into 2 groups: those with pres-
ence or history of extracolonic malignancy and those 
without.  Prevalence of neoplasia was compared between 
the 2 groups.  This database analysis was approved by 
the institutional review board of Okayama University 
Hospital and each aﬃliated hospital.  Informed consent 
was obtained from each patient.
　 Colonoscopic ﬁndings. During the colonos-
copy,  the location and size of all polypoid lesions and 
cancers were determined.  The size of the polyps 
resected with polypectomy or surgical resection was 
measured just after resection.  The polyps that under-
went biopsy alone were measured endoscopically using 
standard clinical practices,  such as visual estimation 
and the open biopsy forceps method [9,  10].
　 Pathologic ﬁndings. Histologic studies were 
performed on all polyps and tumors taken by polypec-
tomy or biopsy procedures by board certiﬁed patholo-
gists at each participating hospital.  CRCs included all 
invasive cancer and cancer in the Tis category (carci-
noma in situ and intramucosal) of the TNM Clinical 
Classiﬁcation [11].  Traditional tubular adenomas 
were classiﬁed as tubular,  tubulovillous,  or villous 
adenomas.  They were also classiﬁed as low or high-
grade according to the degree of dysplasia.  Adenomas 
ｧ10mm,  with a villous component,  or with high-grade 
dysplasia or cancer were deﬁned as advanced neopla-
sia.
　 Statistical analysis. We used the chi-square 
test or Fisherʼs exact test for univariate analysis and 
a logistic regression model in order to adjust for 
confounding factors.  Results are shown as odds ratios 
(ORs) with 95ｵ conﬁdence intervals (CIs).  These 
analyses were performed using the JMP program 
(version 8; SAS Institute,  Cary,  NC,  USA).  All p 
values are two-sided and considered signiﬁcant when 
less than 0.05.
Results
　 Clinical characteristics of analyzed subjects.
Of the 38,786 colonoscopy cases enrolled in this 
study,  26,452 cases were eligible for analysis.  Those 
excluded had insuﬃcient pathological data (n＝9,468),  
prior resection of any part of the colon (n＝273),  
familial adenomatous polyposis (n＝5),  inﬂammatory 
bowel disease (n＝236),  or insuﬃcient clinical data (n
＝2,117),  or were less than 20 years of age (n＝235).  
Of these subjects,  3,026 (11ｵ) subjects had history 
or concomitance of extracolonic primary malignancy,  
while the remaining 23,426 subjects did not.  The 
characteristics of the subjects are shown in Table 1.  
The proportion of males was larger in the subjects 
with history or concomitance of extracolonic malig-
nancy.  In addition,  they were older.  The indications 
for colonoscopy were rather diﬀerent between the 2 
groups; screening was a major indication in subjects 
with extracolonic malignancy,  while nearly half of the 
patients without extracolonic malignancy underwent 
colonoscopy due to a positive fecal occult blood test.
　 Colorectal neoplasia was observed in 39ｵ of all 
the subjects.  The prevalence of any type of neoplasia 
was higher in subjects with extracolonic malignancy 
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than in those without (42ｵ vs. 39ｵ,  p＝0.0012).  A 
crude comparison between the 2 groups revealed no 
diﬀerences in the prevalence of advanced neoplasia and 
cancer.
　 Prevalence of colorectal neoplasia according 
to type of extracolonic malignancy. The preva-
lence of colorectal neoplasia according to the type of 
extracolonic malignancy was examined (Table 2).  The 
prevalence of all neoplasia,  advanced neoplasia,  or 
cancer varied to some extent among subjects with 
major malignancies.  However,  it should be noted that 
the diﬀerence in the prevalence was largely attribut-
able to the gender and age of the patients.  For 
example,  the prevalence of neoplasia in subjects with 
breast or uterine cancer was lower than in those with 
other malignancies.  The prevalence of neoplasia in 
patients with prostate cancer was relatively high,  in 
part due to the older age of those patients.
　 Adjusted ORs for colorectal neoplasia in 
patients with extracolonic malignancy. Because 
the prevalence of colorectal neoplasia was aﬀected by 
patient age and gender,  ORs for occurrence of col-
orectal neoplasia in subjects with extracolonic malig-
nancy were calculated with adjustments for age and 
gender (Table 3).  Intriguingly,  the occurrences of all 
neoplasia,  advanced neoplasia,  and cancer in subjects 
with extracolonic malignancy were shown to be sig-
niﬁcantly less than in the patients without this condi-
tion (OR (95ｵ CIs): 0.87 (0.80-0.94),  0.78 (0.70-
0.87),  and 0.77 (0.66-0.90),  respectively).  Age 
stratiﬁcation revealed that the trend was true and 
statistically signiﬁcant (except for cancer in patients 
between 50-69 years of age) in subjects who were 50 
years old or older.
　 In addition to age and gender,  indication for 
colonoscopy could also be a bias for the prevalence of 
colorectal neoplasia.  Therefore,  ORs were calculated 
with indication for colonoscopy (screening,  positive 
fecal occult blood test,  abdominal symptoms,  and 
rectal bleeding) as a confounding factor.  This analysis 
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Male 14,251 54 1,701 56 12,550 54 0.006
　Female 12,201 46 1,325 44 10,876 46
Age
　Mean±SD, y 65.6±11.5 58.5±14.6 ＜0.0001
　20-49 6,441 24 273  9 6,168 26
　50-69 12,790 48 1,484 49 11,306 48
　70＜ 7,221 27 1,269 42 5,952 25
Indication for colonoscopy ＜0.0001
　Screening 2,401  9 870 29 1,531  7
　Positive fecal occult blood test 11,740 44 782 26 10,958 47
　Abdominal symptoms 5,346 20 471 16 4,875 21
　Rectal bleeding 3,615 14 335 11 3,280 14
　Others 3,350 13 568 19 2,782 12
Colorectal neoplasia
　No neoplasia 16,181 61 1,769 58 14,413 62 0.001
　Neoplasia 10,271 39 1,258 42 9,013 39
　　Adenoma＜9mm 5,936 22 757 25 5,179 22
　　Advanced neoplasia 4,337 16 501 17 3,836 15 NS
　　　Adenoma＞10mm 2,111  8 248  8 1,863  8
　　　Tubulovillous or villous adenoma 281  1 20  1 262  1
　　　High-grade dysplasia 271  1 37  1 234  1
　　　Cancer 1,672  6 196  7 1,476  6 NS
yielded results similar to those described above: the 
occurrences of all neoplasia,  advanced neoplasia,  and 
cancer in patients with extracolonic malignancy were 
found to be signiﬁcantly less than in those without 
extracolonic malignancy (OR (95ｵ CIs): 0.91 (0.83-
0.99),  0.83 (0.74-0.93),  and 0.82 (0.70-0.96),  respec-
tively),  although a majority of the ﬁndings were no 
longer statistically signiﬁcant with age stratiﬁcation.  
These results suggest that presence or history of 
extracolonic malignancy is not a risk factor for col-
orectal neoplasia,  but instead,  carries a lower risk of 
colorectal neoplasia.
　 Although there were diﬀerences in the frequency 
of extracolonic primary malignancy among institutes 
(e.g.,  Okayama University Hospital vs. 5 major aﬃli-
ated hospitals; 28ｵ vs. 8.6-10.1ｵ),  the results were 
not much skewed in the analysis with adjustment of 
institutes (data not shown).
　 Adjusted ORs for colorectal neoplasia 
according to type of extracolonic malignancy.
Finally,  adjusted ORs for colorectal neoplasia were 
calculated according to the type of extracolonic malig-
nancy.  Although most of the 7 major extracolonic 
malignancies showed a trend towards lower risk of 
colorectal neoplasia,  many of them did not reach sta-
tistical signiﬁcance; negative associations were found 
288 Acta Med.  Okayama　Vol.  67,  No.  5Akita et al.
Table 2　 Prevalence of colorectal neoplasia in patients with extracolonic primary malignancy





Extracolonic primary malignancies (－) 23,426 58.5±14.6 9,013 39 3,836 15 1,476 6
Extracolonic primary malignancies (＋) 3,026 65.6±11.5 1,258 42 501 17 196 6
Gastric cancer 842 67.4±10.5 370 44 140 17 57 7
Breast cancer 346 61.8±11.2 102 30 39 11 18 5
Uterine cancer 324 60.9±13.3 90 28 38 12 14 4
Prostatic cancer 261 72.5±6.7 133 51 58 22 22 8
Lung cancer 203 68.4±9.7 90 44 40 20 15 7
Hepatoma 200 66.9±10.1 96 48 34 17 12 6
Esophagial cancer 168 66.6±8.9 99 59 33 20 8 5
others 814 64.3±12.4 336 41 146 18 61 7







All patientsb 0.87 (0.80-0.94)＊＊＊ 0.78 (0.70-0.87)＊＊＊ 0.77 (0.66-0.90)＊＊＊
0.91 (0.83-0.99)＊　　 0.83 (0.74-0.93)＊＊＊ 0.82 (0.70-0.96)＊　　
20-49 yearsc 1.27 (0.94-1.71)　　　 1.22 (0.74-1.90)　　　 1.61 (0.62-3.42)　　　
1.03 (0.74-1.40)　　　 1.00 (0.60-1.60)　　　 1.31 (0.49-2.90)　　　
50-69 yearsc 0.88 (0.79-0.99)＊　　 0.77 (0.66-0.90)＊＊＊ 0.81 (0.64-1.02)　　　
0.92 (0.82-1.04)　　　 0.81 (0.69-0.96)　　　 0.80 (0.62-1.02)　　　
70 years＜c 0.88 (0.77-0.99)＊　　 0.82 (0.70-0.95)＊＊　 0.77 (0.62-0.94)＊　　
0.90 (0.79-1.02)　　　 0.86 (0.73-1.00)　　　 0.82 (0.66-1.02)　　　
aOdds ratio and p value of extra colonic primary malignancies for colorectal neoplasia.  bRelative risk adjusted for age and gender (upper),  
and with additional adjustment for indication for colonoscopy (lower,  bold and italic letters).  cRelative risk adjusted for gender (upper),  and 
with additional adjustment for indication for colonoscopy (lower,  bold and italic letters).  dAll neoplasia including all colorectal adenomas 
and cancers.
＊p＜ .05,  ＊＊p＜ .01,  ＊＊＊p＜ .001
between prostatic cancer and all neoplasia (OR (95ｵ 
CIs): 0.73 (0.58-0.95) and 0.76 (0.59-0.97) after 
adjusting for age/gender and indication for colonos-
copy,  respectively) and advanced neoplasia (OR (95ｵ 
CIs): 0.73 (0.54-0.99) after adjusting for indication 
for colonoscopy) (Table 4).  In particular,  presence or 
history of gastric cancer was found to be associated 
with a signiﬁcantly lower risk of all neoplasia,  advanced 
neoplasia,  and cancer (OR (95ｵ CIs): 0.81 (0.70-
0.94),  0.70 (0.58-0.84),  and 0.75 (0.56-0.97),  respec-
tively).  Even after adjustment for indication for 
colonoscopy,  the lower risk for advanced neoplasia 
remained statistically signiﬁcant (OR (95ｵ CIs):  
0.81 (0.67-0.99)).
　 Only in the case of esophageal squamous cell can-
cer did we ﬁnd a higher risk of colorectal neoplasia 
(OR (95ｵ CIs): 1.38 (1.01-1.90) after adjusting for 
age/gender).  Although the trend was more pronounced 
after adjustment for indication for colonoscopy (OR 
(95ｵ CIs): 1.66 (1.20-2.29)),  no risks of advanced 
neoplasia and cancer were observed.
Discussion
　 Unexpectedly,  we found that the presence or his-
tory of extracolonic primary malignancy was not a risk 
factor for colorectal neoplasia in this large population 
who underwent colonoscopy.  Rather,  those patients 
had a relatively lower risk of colorectal neoplasia than 
subjects without extracolonic malignancy.
　 To the best of our knowledge,  there have been no 
reports that evaluated the risk association between 
extracolonic primary malignancy and colorectal neo-
plasia.  There are common risk factors among cancers 
originating from various organs,  such as alcohol,  
smoking,  etc.  Therefore,  our hypothesis prior to the 
start of this study,  which was that subjects with 
extracolonic malignancy would have a higher risk of 
colorectal neoplasia,  seemed highly plausible.  However,  
our unexpected results suggest that the presence of 
factors that are associated with suppression of col-
orectal neoplasia development override the eﬀects of 
the common carcinogenic risk factors.
　 Although it seems highly unlikely that there are 
deﬁnite genetic or environmental factors that simulta-
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Gastric cancerb 842 0.81 (0.70-0.94)＊＊ 0.70 (0.58-0.84)＊＊＊ 0.75 (0.56-0.97)＊
0.88 (0.76-1.02)　　 0.81 (0.67-0.99)＊　　 0.93 (0.69-1.23)　
Breast cancer (only female)c 346 0.92 (0.73-1.16)　　 0.89 (0.62-1.23)　　　 0.91 (0.54-1.43)　
0.91 (0.72-1.16)　　 0.86 (0.60-1.20)　　　 0.86 (0.51-1.37)　
Uterine cancer (only female)c 324 0.86 (0.67-1.10)　　 0.94 (0.65-1.31)　　　 0.74 (0.41-1.23)　
0.89 (0.69-1.14)　　 0.93 (0.64-1.30)　　　 0.86 (0.51-1.37)　
Prostatic cancer (only male)c 261 0.73 (0.58-0.95)＊　 0.75 (0.55-1.01)　　　 0.75 (0.47-1.14)　
0.76 (0.59-0.97)＊　 0.73 (0.54-0.99)＊　　 0.69 (0.43-1.06)　
Lung cancerb 203 0.84 (0.63-1.11)　　 0.88 (0.61-1.23)　　　 0.82 (0.46-1.34)　
0.77 (0.58-1.03)　　 0.77 (0.53-1.09)　　　 0.68 (0.38-1.13)　
Hepatomab 200 1.01 (0.76-1.34)　　 0.75 (0.51-1.08)　　　 0.69 (0.36-1.19)　
1.03 (0.77-1.38)　　 0.77 (0.52-1.12)　　　 0.70 (0.37-1.23)　
Esophagial cancerb 168 1.38 (1.01-1.90)＊　 0.81 (0.54-1.18)　　　 0.52 (0.23-1.00)　
1.66 (1.20-2.29)＊＊ 1.12 (0.73-1.65)　　　 0.79 (0.35-1.56)　
aAll neoplasia including all colorectal adenomas and cancers.  bRelative risk adjusted for age and gender (upper),  and with additional 
adjustment for indication for colonoscopy (lower,  bold and italic letters).  cRelative risk adjusted for age (upper),  and with additional adjust-
ment for indication for colonoscopy (lower,  bold and italic letters).
＊p＜ .05,  ＊＊p＜ .01,  ＊＊＊p＜ .001
neously suppress colon carcinogenesis and promote 
carcinogenesis of other types of cancer,  those who are 
likely to develop colorectal neoplasia may have a pre-
disposition to escape from development of other types 
of cancer.  For example,  there may be microorgan-
isms in the gut ﬂora that directly injure the colorectal 
epithelium,  but may also indirectly prevent other 
types of cancer by activating the immune system.  
Further data and considerations are needed to resolve 
this issue.
　 Another explanation for our results is that the 
presence or experience of any type of cancer would 
render patients more health-conscious,  such that they 
may take actions to improve of their health,  including 
quitting or reducing smoking or drinking,  increase in 
physical activity,  or taking supplements.  In fact,  it 
has been reported that patients with head and neck 
cancer who stopped smoking and drinking after treat-
ment were less likely to develop metachronous cancer 
than those who did not [12].  Moreover,  once patients 
have suﬀered from any type of cancer,  they will be 
more likely to seek medical examination in response to 
slight or marginal symptoms.  And of course,  subjects 
with only slight symptoms would be less likely to 
harbor colorectal neoplasia than those with pro-
nounced symptoms.  Thus,  presence or history of 
malignancy could change the patientsʼ attitude towards 
health care,  possibly resulting in less prevalence of 
colorectal neoplasia.
　 In our study,  CRC screening was a major indica-
tion for colonoscopy in subjects with extracolonic 
malignancy,  although this was rather rare in those 
without extracolonic malignancy.  There may be 2 
reasons for this tendency.  First,  clinicians were 
likely to be anxious about concomitance of other 
malignancies following the discovery of one malig-
nancy.  Second,  when patients with 1 type of cancer 
are scheduled to undergo surgery,  particularly 
abdominal surgery,  it is important to know whether 
colonic lesions are present so that they can dealt with 
simultaneously.  It appears to be natural that asymp-
tomatic subjects who underwent colonoscopy with 
indication of CRC screening were less likely to have 
colonic lesions than subjects who had abdominal symp-
toms or a positive fecal occult blood test result.  To 
correct this bias,  we adjusted for indications for 
colonoscopy as well as gender and age.  In addition,  
we analyzed the subjects with each indication sepa-
rately,  to compare the results for each indication with 
the results of the analysis of all subjects (data not 
shown).  The ﬁndings indicated that history or con-
comitance of extracolonic malignancy is deﬁnitely not 
a risk factor for colonic neoplasia.
　 Presence or history of gastric cancer,  the most 
prevalent malignancy in Japan,  also was not correlated 
with increased risk of colorectal neoplasia; in fact,  it 
was correlated with a decreased risk of advanced 
colorectal neoplasia.  The most potent risk factor of 
gastric cancer is Helicobacter pylori (H. pylori) infection.  
Several reports have indicated that H. pylori infection 
is correlated with increased risk of colorectal neopla-
sia,  although this risk is not as great as that for gas-
tric cancer [13,  14].  Long-term continuous H. pylori 
infection causes atrophic gastritis,  from which gastric 
cancer develops.  Inoue et al.  reported that although 
H. pylori infection is a risk factor for colorectal ade-
noma,  the presence of atrophic gastritis is not a par-
ticularly great risk for distal colorectal adenoma 
[15].  This suggests that the progression of gastric 
atrophy due to H. pylori infection lowers the risk of 
distal colorectal neoplasia.  A subanalysis of our results 
on the location of colorectal neoplasia indicated that 
presence or history of gastric cancer signiﬁcantly 
lowered the risk of distal colorectal neoplasia,  but this 
trend was not observed in the risk of proximal col-
orectal neoplasia (distal neoplasia: OR＝0.78 (0.67-
0.91),  p＝0.002; proximal neoplasia: OR＝0.90 (0.76-
1.05),  p＝0.19).  Those who are predisposed to gastric 
cancer occurrence usually have atrophic gastritis,  
irrespective of whether or not they currently have or 
previously had H. pylori infection.  Therefore,  subjects 
who developed gastric cancer might have lower risk for 
distal colorectal neoplasia.
　 In our analysis,  esophageal squamous cell cancer 
was the only malignancy that carried a higher risk of 
colorectal neoplasia.  The predominant risk factors of 
esophageal cancer are smoking and alcohol consump-
tion [16],  which are also those of various other can-
cers,  including CRC.  Although it is largely unknown 
why esophageal cancer alone was correlated with the 
occurrence of colorectal neoplasia,  polymorphism of 
enzymes metabolizing alcohol may be partially respon-
sible.  The aldehyde dehydrogenase Glu504Lys poly-
morphism is correlated with increased risk of esopha-
geal cancer [17].  This polymorphism is also correlated 
with occurrence of colorectal cancer,  particularly 
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among alcoholics [18].  Because esophageal cancer is 
likely to develop in heavy drinkers,  heavy drinking 
and the predisposing polymorphism may signiﬁcantly 
aﬀect the development of colorectal neoplasia in 
esophageal cancer patients.
　 There are limitations to this study.  First,  some of 
the enrolled patients may have had hereditary cancers,  
despite the fact that the family history was carefully 
investigated.  In particular,  patients with Lynch syn-
drome are known to have both colorectal and extraco-
lonic cancers,  particularly gastric cancer [19].  However,  
Lynch syndrome has been reported to account for only 
0.4ｵ of CRC cases in Japan [20].  Second,  the 
prevalence of H. pylori infection in the general popula-
tion in Japan,  where this study was performed,  tends 
to be higher than that of Western subjects [21].  In 
addition,  the aldehyde dehydrogenase Glu504Lys 
polymorphism is much more common in Asian than in 
Caucasian populations [22].  The high prevalence of 
H. pylori infection and the predisposing polymorphism 
probably aﬀected the results of our study with regard 
to gastric and esophageal cancers,  respectively.  
Third,  this study was based on analyses of colonos-
copy database.  To more accurately investigate the 
eﬀect of extracolonic malignancy on the presence of 
colorectal neoplasia,  a large scale population-based 
study is required.  Moreover,  information about 
extracolonic malignancy were collected from a ques-
tionnaire written by patients on the day of colonos-
copy.  Therefore,  the presence of subclinical extraco-
lonic malignancy could not be examined accurately.  
Finally,  there may have been a bias because patients 
with a history of cancer are likely to pay more atten-
tion to their health.  Despite these limitations,  how-
ever,  our ﬁndings will clearly be useful at the clinical 
level for sparing some patients from needless addi-
tional CRC screenings.
　 In conclusion,  patients with presence or history of 
extracolonic malignancy did not carry a higher risk of 
occurrence of colorectal neoplasia; rather,  those patients 
had a relatively lower risk of colorectal neoplasia.  
Therefore,  those who currently have or previously 
had an extracolonic malignancy can be regarded as 
being at average-risk for CRC and do not need to 
receive any special CRC screening.
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